Traders should monitor post-offering price action for TSHA given the 13.6% discount to prior close, anticipate near-term selling pressure as the market absorbs ~32.5M new shares. The 60-day lockup on insiders/executives limits insider selling, but underwriters may release shares early. Key catalysts: REVEAL pivotal trial 6-month interim analysis (topline data expected H1 2027) and FDA Type C meeting follow-up. Pro forma cash of ~$464M removes near-term financing risk and funds BLA preparation.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 26 $6.34entry
- T+1 · 5mo ago +6.15%α +4.50% · $6.73
- T+5 · 4mo ago +3.00%α +0.83% · $6.53
- T+20 · 4mo ago −8.04%α −9.30% · $5.83
- T+60 · 8w ago −20.50%α −26.61% · $5.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised) through the sale of 32.5M shares of common stock and pre-funded warrants at $6.00 per share, representing a 13.6% discount to the $6.94 prior closing price. Net proceeds combined with existing $276.6M cash will fund TSHA-102 BLA preparation/commercial launch and pipeline development, extending runway into H2 2028. The offering creates immediate 79% dilution ($4.75/share) for new investors.
Key Facts
- Offering of 32,500,001 shares of common stock at $6.00/share, a 13.6% discount to the prior close of $6.94
- Pre-funded warrants for up to 833,333 additional shares at $5.999 per warrant (exercise price $0.001)
- Net proceeds estimated at $187.4M (or $215.6M with underwriter option exercise)
- Immediate dilution of $4.75 per share for new investors (79% of offering price)
- Post-offering shares outstanding increase to 319,776,886 from 287,276,885 (11.3% increase)
- Cash and equivalents of $276.6M as of March 31, 2026; pro forma cash ~$464M
- Underwriters have 30-day option to purchase 5,000,000 additional shares
Financial Impact
Gross proceeds of $200M; net proceeds ~$187.4M after underwriting discounts and expenses. Immediate dilution of $4.75/share (79%) to new investors at $6.00 offering price. Post-offering cash runway extended to H2 2028.
Risk Factors
- Significant immediate dilution (79%) may pressure stock price
- Pre-funded warrant exercises could add further dilution
- Clinical-stage biotech with no approved products, regulatory/clinical risk remains high
- Underwriters may release lock-up shares early, increasing supply
- Cash burn rate for clinical/CMC activities could accelerate if trials expand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-282846 |
| Document: d95601dexfilingfees.htm | 0001193125-26-282846 |
| Document: 0001193125-26-282846-index-headers.html | 0001193125-26-282846 |
| Document: 0001193125-26-282846-index.html | 0001193125-26-282846 |
| Document: 0001193125-26-282846.txt | 0001193125-26-282846 |
Track record
14 reports on TSHA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Viewing Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers